Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

This publication has 46 references indexed in Scilit:

• Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD
  Clinical Journal of the American Society of Nephrology, 2010
• Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease
  Bone, 2009
• Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols
  Pediatric Nephrology, 2009
• Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
  Circulation, 2009
• Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis
  The Journal of Clinical Endocrinology & Metabolism, 2009
• Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
  New England Journal of Medicine, 2008
• Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients
  Journal of the American Society of Nephrology, 2008
• Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
  Kidney International, 2007
• Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
  Kidney International, 1997
• 25-Hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: Beneficial effect on linear growth velocity
  The Journal of Pediatrics, 1982